Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients
Top Cited Papers
Open Access
- 3 October 2013
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 122 (14), 2412-2424
- https://doi.org/10.1182/blood-2013-02-482125
Abstract
Key Points MCL cells are mobilized into the peripheral blood of patients treated with the BTK inhibitor ibrutinib. Ibrutinib dose-dependently inhibits BCR- and chemokine-mediated adhesion and migration of MCL cells.This publication has 54 references indexed in Scilit:
- New molecular targets in mantle cell lymphomaSeminars in Cancer Biology, 2011
- CD38 and chronic lymphocytic leukemia: a decade laterBlood, 2011
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood, 2011
- Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signalingCellular Oncology, 2011
- The lymph node microenvironment promotes B-cell receptor signaling, NF-κB activation, and tumor proliferation in chronic lymphocytic leukemiaBlood, 2011
- Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic eraBlood, 2011
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancyProceedings of the National Academy of Sciences of the United States of America, 2010
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaBlood, 2010
- Protein Profiling of Plasma Membranes Defines Aberrant Signaling Pathways in Mantle Cell LymphomaMolecular & Cellular Proteomics, 2009
- Balanced responsiveness to chemoattractants from adjacent zones determines B-cell positionNature, 2002